Catalyst Pharmaceutical Research to Present CPP-115 Progress at the 2012 College on Problems of Drug Dependence Symposium

CORAL GABLES, Fla., June 7, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will present "CPP-115: A Second-Generation GABA Aminotransferase Inhibitor" during a symposium at the 74th Annual Meeting of the College on Problems of Drug Dependence (CPDD), which is being held at the La Quinta Resort and Club in Palm Springs, California on June 9th through June 14th.

Back to news